TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 3737634
Drug: Phenylpropanolamine (PPA)
DrugBank: Phenylpropanolamine (DB00397)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Phenylpropanolamine (PPA) 25 mg
Study: 3737634
Drug: Phenylpropanolamine (PPA)
DrugBank: Phenylpropanolamine (DB00397)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Phenylpropanolamine (PPA) 75 mg
Study: 3737634
Drug: Mazindol (MAZ)
Normalized name: Mazindol
DrugBank: Mazindol (DB00579)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mazindol (MAZ) 0.5 mg
Study: 3737634
Drug: Mazindol (MAZ)
Normalized name: Mazindol
DrugBank: Mazindol (DB00579)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mazindol (MAZ) 2.0 mg
Study: 3737634
Drug: D-amphetamine (AMP)
Normalized name: amphetamine / dextroamphetamine
DrugBank: Dextroamphetamine (DB01576)
Approvals — FDA: no, EMA: no, PMDA: no
Description: D-amphetamine (AMP) 10 mg
Study: 29388417
Drug: Tooth-borne distraction
Normalized name: Sus scrofa tooth preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tooth-borne distraction osteogenesis (DO); activated twice daily by a total amount of 0.5 mm per day for 3 weeks after a 7-day latency period.
Study: 20675956
Drug: Angiotensin II-receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Angiotensin II-receptor blockers (ARBs)
Study: 18728281
Drug: ACE inhibitors
Normalized name: ACE INHIBITORS
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACE inhibitors or ARBs
Study: 18436085
Drug: Individualized dietary
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individualized dietary counseling with regular follow-up (aimed at achieving an intake of 0.8 to 1.0 g/kg of protein and greater than 125 kJ/kg of energy)
Study: 17283863
Drug: Azelnidipine 8‐16
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azelnidipine 8‐16 mg/day
Study: 10805607
Drug: EHR (Progynova
Approvals — FDA: no, EMA: no, PMDA: no
Description: EHR (Progynova TS, transdermal estradiol; n=19)
Study: 8793308
Drug: Residential relapse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Residential relapse prevention/health education treatment
Study: 1451289
Drug: Topical fish
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical fish oil (FO) applied daily for 6 hours under an occlusive dressing for 4 weeks
Study: 1451289
Drug: Liquid paraffin
Normalized name: Liquid paraffin
DrugBank: Mineral oil (DB11057)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liquid paraffin (LP) applied daily for 6 hours under an occlusive dressing for 4 weeks
Study: 1451289
Drug: Topical fish
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical fish oil (FO)
Study: 26907502
Drug: Wii-based Movement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wii-based Movement Therapy (WMT)
Study: 26907502
Drug: modified Constraint‐induced
Approvals — FDA: no, EMA: no, PMDA: no
Description: modified Constraint‐induced Movement Therapy (mCIMT)
Study: 12370217
Drug: ezetimibe (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: ezetimibe (10 mg/d)
Study: 19965915
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (ezetimibe + simvastatin)
Study: 18340009
Drug: 20 mg/d
Normalized name: Valtoco, 20 mg/dose nasal spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg/d fluvastatin
Study: 16007894
Drug: External beam
Normalized name: Beam
DrugBank: Tricyclazole (DB02891)
Approvals — FDA: no, EMA: no, PMDA: no
Description: External beam RT as a postoperative adjunct
Study: 12429759
Drug: Extracorporeal shock
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Extracorporeal shock wave therapy with three treatments of 2000 pulses each and a positive energy flux density (ED+) of 0.07 to 0.09 mJ/mm²
Study: 12429759
Drug: Extracorporeal shock
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Extracorporeal shock wave therapy and Placebo therapy
Study: 7826828
Drug: Fluvastatin 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvastatin 2.5 mg day-1
Study: 7826828
Drug: Fluvastatin 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvastatin 5 mg day-1
Study: 7826828
Drug: Fluvastatin 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvastatin 10 mg day-1
Study: 7826828
Drug: Fluvastatin 20
Normalized name: fluvastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvastatin 20 mg day-1
Study: 2901122
Drug: Acebutolol (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acebutolol (400 mg once daily)
Study: 23827820
Drug: Jitai tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Jitai tablets (JTT)
Study: 20629478
Drug: Lactose doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactose doses of 0-2 grams (lactose-reduced solution/milk)
Study: 20629478
Drug: Varying lactose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Varying lactose doses
Study: 20629478
Drug: Other agents
Normalized name: Other agents for local oral treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other agents (not specified)
Study: 20629478
Drug: Lactose doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactose doses of 12-15 grams
Study: 20629478
Drug: Lactose doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactose doses above 12 grams
Study: 3945045
Drug: Ferrous sulphate
Normalized name: Ferrous sulphate
DrugBank: Ferrous fumarate (DB14491)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ferrous sulphate (80 mg Fe++ three times daily) for 6 weeks
Study: 6692967
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no iron therapy)
Study: 30215785
Drug: 21‐mg nicotine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 21‐mg nicotine patch for 24 weeks with behavior counseling
Study: 30215785
Drug: 21‐mg nicotine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 21‐mg nicotine patch for 8 weeks with behavior counseling
Study: 30215785
Drug: 21‐mg nicotine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 21‐mg nicotine patch for 52 weeks with behavior counseling
Study: 20027108
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg intravenous rolofylline, 4-hour infusions once daily for 4 consecutive days
Study: 20027108
Drug: Single oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose of midazolam 7.5 mg
Study: 20027108
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg intravenous rolofylline
Study: 10586391
Drug: Theophylline (IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theophylline (IV infusion)
Study: 10586391
Drug: Amikacin (IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amikacin (IV infusion)
Study: 23879234
Drug: Mometasone furoate
Normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mometasone furoate (MMF) 0.1% ointment for 12 weeks
Study: 21878580
Drug: Se+highI (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Se+highI (100 μg selenium + >50 mg iodine as iodate/day for 8 weeks)
Study: 21878580
Drug: highI (>50
Approvals — FDA: no, EMA: no, PMDA: no
Description: highI (>50 mg iodine as iodate/day for 8 weeks)
Study: 21878580
Drug: Se+lowI (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Se+lowI (80 μg iodine as iodate/day + selenium)
Study: 21878580
Drug: lowI (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: lowI (80 μg iodine as iodate/day without selenium)
Study: 18645345
Drug: Dopamine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dopamine infusion (0.5-3 microg/kg/min)
Study: 7528949
Drug: High-dose aprotinin
Normalized name: Aprotinin
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High-dose aprotinin (Trasylol)
Study: 8655886
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate aqueous nasal spray (200 micrograms once daily)
Study: 3966746
Drug: Delay in
Normalized name: Delayed Release Oral Granules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delay in initiation of treatment
Study: 30917302
Drug: 0.15% benzydamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.15% benzydamine hydrochloride (Tantum Verde®) mouthwash solution
Study: 23241227
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment (Ranibizumab + PDT)
Study: 21496998
Drug: Hilotherm cooling
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hilotherm cooling therapy
Study: 19085267
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of sedating H1 antihistamine and non‐sedating H1 antihistamine (Group A)
Study: 19085267
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of H1 antihistamine and H2 antihistamine (Group B)
Study: 19085267
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of H1 antihistamine and leukotriene receptor antagonist (LRA) (Group C)
Study: 19085267
Drug: Matched placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched placebo medication (Group D)
Study: 14630840
Drug: Oral alendronate
Normalized name: alendronate
DrugBank: Alendronic acid (DB00630)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral alendronate at a dose of 10 mg/day for six months
Study: 10832506
Drug: Sahaja Yoga
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sahaja Yoga meditation twice daily for 6 months
Study: 2951793
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of fenoterol and ipratropium bromide (Duovent)
Study: 24894416
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (non-SSRIs)
Study: 1460149
Drug: Various forms
Normalized name: various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Various forms of treatment for depression
Study: 6376207
Drug: Chlorthalidone 25
Normalized name: chlorthalidone 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorthalidone 25 mg/triamterene 50 mg
Study: 10395628
Drug: Live-culture yogurt
Normalized name: casein, emmental cultured
Approvals — FDA: no, EMA: no, PMDA: no
Description: Live-culture yogurt (200 g/d for 1 year)
Study: 10395628
Drug: Pasteurized yogurt
Normalized name: Human fibrinogen concentrate, pasteurized
DrugBank: Fibrinogen human (DB09222)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pasteurized yogurt (200 g/d for 1 year)
Study: 2160356
Drug: Plasma parathyroid
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Plasma parathyroid hormone
Study: 2160356
Drug: Discriminant function
Normalized name: plasma protein fraction Injection [Plasmanate]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discriminant function based on parathyroid hormone and alkaline phosphatase
Study: 25369827
Drug: Probiotic (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic (5 × 10(9) CFUs; twice daily)
Study: 22901562
Drug: Resveratrol (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resveratrol (250 mg/d) along with oral hypoglycemic agents
Study: 22901562
Drug: Oral hypoglycemic
Normalized name: ORAL HYPOGLYCEMIC AGENTS,ORAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral hypoglycemic agents only
Study: 11328262
Drug: Aspirin (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (400 mg b.d.)
Study: 11328262
Drug: Aspirin (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (400 mg b.d.) + Vitamin C (480 mg b.d.)
Study: 9877109
Drug: Calcium infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium infusion rate varied to produce a fall of at least 0.2 mmol/l in ionized calcium during hemodialysis.
Study: 9877109
Drug: Calcium infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium infusion rate maintained stable ionized calcium during hemodialysis.
Study: 172181
Drug: Natural oestrogen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Natural oestrogen administration
Study: 172181
Drug: Synthetic oestrogen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Synthetic oestrogen administration with oral contraception
Study: 28664557
Drug: Oxygen therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxygen therapy (O2)
Study: 19168107
Drug: DNA vaccine
Normalized name: HTNV DNA vaccine
DrugBank: Hantaan virus DNA vaccine (DB17808)
Approvals — FDA: no, EMA: no, PMDA: no
Description: DNA vaccine (intramuscularly or intradermally)
Study: 15285057
Drug: 100 ml
Normalized name: PVC IV Bag 100 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 ml of Iohexol 300
Study: 15285057
Drug: 75 ml
Normalized name: ethanol 0.75 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 ml of Ioversol 320
Study: 9630829
Drug: OPC‐31260 (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: OPC‐31260 (30 mg, orally)
Study: 7946238
Drug: Regular use
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular use of medication with family intervention
Study: 29932590
Drug: Phase II
Normalized name: Coxiella burnetii phase II Ab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phase II intervention (3 monthly classes, 60 minutes each, postpartum)
Study: 20026575
Drug: Adjustment group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjustment group intervention (six, 2-hour group treatment sessions)
Study: 12810245
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with pioglitazone (30 mg/day) plus metformin
Study: 12810245
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with pioglitazone (15 or 30 mg/day) plus sulfonylurea
Study: 9148020
Drug: Detection of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Detection of anti-neutrophil cytoplasmic antibodies (ANCA)
Study: 9148020
Drug: Absorption of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Absorption of sera with actin
Study: 8342184
Drug: Low-dose acetylsalicylic
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose acetylsalicylic acid (ASA) 75 mg/d for 6 months
Study: 3538957
Drug: Monitored group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monitored group (theophylline dosages adjusted daily based on estimated clearance)
Study: 27462118
Drug: Intravenous albumin
Normalized name: albumin human, USP Injection [Albuminar]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous albumin 25% at 2 g/kg
Study: 24766978
Drug: Ezetimibe prescriptions
Normalized name: Ezetimibe
DrugBank: Ezetimibe (DB00973)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ezetimibe prescriptions in the US
Study: 24766978
Drug: Ezetimibe prescriptions
Normalized name: Ezetimibe
DrugBank: Ezetimibe (DB00973)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ezetimibe prescriptions in Canada
Study: 24365167
Drug: 6% HES
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6% HES 130/0.4 plus lactated Ringer's solution
Study: 24365167
Drug: lactated Ringer's
Normalized name: LACTATED RINGER'S
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: lactated Ringer's solution
Study: 18180340
Drug: Docosahexaenoic acid
Normalized name: docosahexaenoic acid
DrugBank: Doconexent (DB03756)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docosahexaenoic acid (400 mg/d)
Study: 12608556
Drug: Blood flow
Normalized name: NITRIC OXIDE 400 mg in 500 mg TOPICAL CAPSULE [Bio NO Brain Care (Helps improve Brain blood flow and body temperature, Fermented Garlic powder)]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blood flow at 200 ml/min
Study: 12608556
Drug: Blood flow
Normalized name: NITRIC OXIDE 400 mg in 500 mg TOPICAL CAPSULE [Bio NO Brain Care (Helps improve Brain blood flow and body temperature, Fermented Garlic powder)]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blood flow at 250 ml/min
Study: 12608556
Drug: Blood flow
Normalized name: NITRIC OXIDE 400 mg in 500 mg TOPICAL CAPSULE [Bio NO Brain Care (Helps improve Brain blood flow and body temperature, Fermented Garlic powder)]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blood flow at 300 ml/min
Study: 8635384
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy (cisplatin 50 mg/m2 or 100 mg/m2 plus 3 g/m2 ifosfamide and 6 mg/m2 mitomycin)
Study: 30652260
Drug: Off-label topical
Normalized name: Off! Explore Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Off-label topical therapies (e.g., prostaglandin analogs, polyphenols like latanoprost and procyanidin oligomers)
Study: 26684457
Drug: Intravenous parecoxib
Normalized name: parecoxib
DrugBank: Parecoxib (DB08439)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Intravenous parecoxib sodium 1 mg·kg(‐1) (Group P, n = 30)
Study: 26684457
Drug: Intravenous parecoxib
Normalized name: parecoxib
DrugBank: Parecoxib (DB08439)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Intravenous parecoxib sodium 1 mg·kg(‐1) (Group P)
Study: 18974283
Drug: Teduglutide 50
Normalized name: Teduglutide
DrugBank: Teduglutide (DB08900)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Teduglutide 50 mg/mL and 20 mg/mL formulations
Study: 18974283
Drug: Teduglutide 50
Normalized name: Teduglutide
DrugBank: Teduglutide (DB08900)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Teduglutide 50 mg/mL formulation
Study: 18974283
Drug: Teduglutide 20
Normalized name: Teduglutide
DrugBank: Teduglutide (DB08900)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Teduglutide 20 mg/mL formulation (1.0 mL)
Study: 18974283
Drug: Teduglutide treatments
Normalized name: Teduglutide
DrugBank: Teduglutide (DB08900)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Teduglutide treatments
Study: 18974283
Drug: Injection site
Normalized name: Dual Injection Site
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection site pain
Study: 31663980
Drug: Transcribed list
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transcribed list of six treatment recommendations
Study: 31663980
Drug: Verbal discussion
Normalized name: HERBAL MISCELLANEOUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verbal discussion of six treatment recommendations
Study: 24952869
Drug: Dexamethasone (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (1 mg/kg intraoperatively)
Study: 20634438
Drug: Fluconazole (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluconazole (200 mg every 48 hours)
Study: 17178938
Drug: Ofloxacin otic
Normalized name: ofloxacin otic
DrugBank: Ofloxacin (DB01165)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ofloxacin otic drops
Study: 17178938
Drug: Neomycin-polymyxin B
Normalized name: Dexamethasone-Neomycin-Polymyxin B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neomycin-polymyxin B otic drops
Study: 17178938
Drug: No postoperative
Approvals — FDA: no, EMA: no, PMDA: no
Description: No postoperative otic drop prophylaxis (Control group)
Study: 14574830
Drug: Methylphenidate 10
Normalized name: dexmethylphenidate 10.4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylphenidate 10 mg 3 times daily for 2 weeks
Study: 14574830
Drug: Methylphenidate 15
Normalized name: METHYLPHENIDATE 15MG/9HR PATCH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylphenidate 15 mg 3 times daily for 2 weeks
Study: 10782522
Drug: Sublingual-swallow immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual-swallow immunotherapy (SLIT) with a standardized Dermatophagoides pteronyssinus (D.pt.) - D. farinae (D.f) 50/50 extract, mean cumulative dose of 90,000 IR (2.2 mg of Der p 1 and 1.7 mg of Der f I) for 24 months.
Study: 10782522
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment for 24 months.
Study: 8633933
Drug: Standard cold
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard cold topical irrigation
Study: 1727165
Drug: Methylprednisolone (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylprednisolone (30 mg/kg bolus and 5.4 mg/kg/hr for 23 hours)
Study: 1727165
Drug: Naloxone (5.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone (5.4 mg/kg bolus and 4.0 mg/kg/hr for 23 hours)
Study: 6376653
Drug: 14-valent streptococcus
Approvals — FDA: no, EMA: no, PMDA: no
Description: 14-valent streptococcus pneumoniae polysaccharide vaccine
Study: 27295927
Drug: Immediate implant
Normalized name: IR-3535
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate implant placement with immediately loaded mandibular overdenture
Study: 27295927
Drug: Delayed implant
Normalized name: Drug Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed implant placement with immediately loaded mandibular overdenture
Study: 25428140
Drug: Treatment for
Normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment for ADHD symptoms and IPV, duration of treatment is one year with assessments at t0, 8, 16, 24, and 52 weeks.
Study: 24341093
Drug: Cefoxitin sodium
Normalized name: Cefoxitin Sodium
DrugBank: Cefoxitin (DB01331)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefoxitin sodium iv at 1.0 g 30 minutes before complete urodynamic examination
Study: 10967001
Drug: No pre-treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No pre-treatment (Control)
Study: 20026265
Drug: Strontium ranelate
Normalized name: Strontium ranelate
DrugBank: Strontium ranelate (DB09267)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Strontium ranelate 2 g/d
Study: 18084691
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg daily oral DHEA supplementation for one year
Study: 9344324
Drug: Doxorubicin-ifosfamide combination
Normalized name: Ifosfamide
DrugBank: Ifosfamide (DB01181)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxorubicin-ifosfamide combination chemotherapy
Study: 28295802
Drug: Cognitive therapy
Normalized name: cognitive therapy software
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive therapy based on the Clark and Wells model
Study: 21508389
Drug: CAPOX treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: CAPOX treatment (capecitabine plus oxaliplatin) with bevacizumab
Study: 16669956
Drug: Alicaforsen enema
Normalized name: Alicaforsen
DrugBank: Alicaforsen (DB06224)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alicaforsen enema (240 mg daily for 6 weeks)